These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34028533)

  • 61. Current Drug Treatment Strategies for Atrial Fibrillation and TASK-1 Inhibition as an Emerging Novel Therapy Option.
    Kraft M; Büscher A; Wiedmann F; L'hoste Y; Haefeli WE; Frey N; Katus HA; Schmidt C
    Front Pharmacol; 2021; 12():638445. PubMed ID: 33897427
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Perspectives and limitations in the treatment of vagus-induced atrial fibrillation. Insights from cellular pharmacology].
    Brandts B; Van Bracht M; Dirkmann D; Borchard R; Wickenbrock I; Prull MW; Meine M; Trappe HJ
    Med Klin (Munich); 2004 Jul; 99(7):341-6. PubMed ID: 15322712
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Inhibition of potassium currents is involved in antiarrhythmic effect of moderate ethanol on atrial fibrillation.
    Yang B; Li C; Sun J; Wang X; Liu X; Yang C; Chen L; Zhou J; Hu H
    Toxicol Appl Pharmacol; 2017 May; 322():89-96. PubMed ID: 28284858
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine.
    Burashnikov A; Di Diego JM; Zygmunt AC; Belardinelli L; Antzelevitch C
    Circulation; 2007 Sep; 116(13):1449-57. PubMed ID: 17785620
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Revealing kinetics and state-dependent binding properties of I
    Ellinwood N; Dobrev D; Morotti S; Grandi E
    Chaos; 2017 Sep; 27(9):093918. PubMed ID: 28964116
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation.
    Burashnikov A; Di Diego JM; Zygmunt AC; Belardinelli L; Antzelevitch C
    Ann N Y Acad Sci; 2008 Mar; 1123():105-12. PubMed ID: 18375582
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Characterization of in vivo and in vitro electrophysiological and antiarrhythmic effects of a novel IKACh blocker, NIP-151: a comparison with an IKr-blocker dofetilide.
    Hashimoto N; Yamashita T; Tsuruzoe N
    J Cardiovasc Pharmacol; 2008 Feb; 51(2):162-9. PubMed ID: 18287884
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of antiarrhythmic drugs on small conductance calcium - activated potassium channels.
    Simó-Vicens R; Sauter DRP; Grunnet M; Diness JG; Bentzen BH
    Eur J Pharmacol; 2017 May; 803():118-123. PubMed ID: 28322838
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The human cardiac K2P3.1 (TASK-1) potassium leak channel is a molecular target for the class III antiarrhythmic drug amiodarone.
    Gierten J; Ficker E; Bloehs R; Schweizer PA; Zitron E; Scholz E; Karle C; Katus HA; Thomas D
    Naunyn Schmiedebergs Arch Pharmacol; 2010 Mar; 381(3):261-70. PubMed ID: 19777211
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Potassium channel blocking 1,2-bis(aryl)ethane-1,2-diamines active as antiarrhythmic agents.
    Kajanus J; Antonsson T; Carlsson L; Jurva U; Pettersen A; Sundell J; Inghardt T
    Bioorg Med Chem Lett; 2019 May; 29(10):1241-1245. PubMed ID: 30879840
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization.
    Singh BN; Mody FV; Lopez B; Sarma JS
    Am J Cardiol; 1999 Nov; 84(9A):161R-173R. PubMed ID: 10568677
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Vernakalant: A novel agent for the termination of atrial fibrillation.
    Finnin M
    Am J Health Syst Pharm; 2010 Jul; 67(14):1157-64. PubMed ID: 20592320
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Atrial fibrillation: Therapeutic potential of atrial K
    Ravens U; Odening KE
    Pharmacol Ther; 2017 Aug; 176():13-21. PubMed ID: 27742566
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Piezo1 and BK
    Jakob D; Klesen A; Allegrini B; Darkow E; Aria D; Emig R; Chica AS; Rog-Zielinska EA; Guth T; Beyersdorf F; Kari FA; Proksch S; Hatem SN; Karck M; Künzel SR; Guizouarn H; Schmidt C; Kohl P; Ravens U; Peyronnet R
    J Mol Cell Cardiol; 2021 Sep; 158():49-62. PubMed ID: 33974928
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effects of the selective KACh channel blocker NTC-801 on atrial fibrillation in a canine model of atrial tachypacing: comparison with class Ic and III drugs.
    Yamamoto W; Hashimoto N; Matsuura J; Machida T; Ogino Y; Kobayashi T; Yamanaka Y; Ishiwata N; Yamashita T; Tanimoto K; Miyoshi S; Fukuda K; Nakaya H; Ogawa S
    J Cardiovasc Pharmacol; 2014 May; 63(5):421-7. PubMed ID: 24805146
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model.
    Courtemanche M; Ramirez RJ; Nattel S
    Cardiovasc Res; 1999 May; 42(2):477-89. PubMed ID: 10533583
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Effects of docosahexaenoic acid on atrial physiological parameter and TASK-1 protein expression in atrial fibrillation rats].
    Ge M; Shan F; Tang B; Hou XJ
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2016 Feb; 32(2):128-131. PubMed ID: 29931863
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.
    Tsuji Y; Dobrev D
    Vasc Health Risk Manag; 2013; 9():165-75. PubMed ID: 23637539
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Theoretical possibilities for the development of novel antiarrhythmic drugs.
    Varró A; Biliczki P; Iost N; Virág L; Hála O; Kovács P; Mátyus P; Papp JG
    Curr Med Chem; 2004 Jan; 11(1):1-11. PubMed ID: 14754422
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Rate-Dependent Role of I
    Aguilar M; Feng J; Vigmond E; Comtois P; Nattel S
    Biophys J; 2017 May; 112(9):1997-2010. PubMed ID: 28494969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.